Hospices Civils de Lyon
Bron, 69800, France
NCT Number: NCT07616726
With more than 3,000 new cases per year in France, malignant gliomas are the most common malignant brain tumors in adults.
Treatment consists of surgical removal when possible. If this is not possible, a biopsy is performed to obtain a definitive anatomical and molecular diagnosis. Standard medical management after removal or biopsy is based on radio-chemotherapy. Despite this multimodal treatment, progression is the norm due to the invasive nature of these tumors. The prognosis remains very poor, with a median overall survival of around 18 months for glioblastomas.
Recent preliminary data indicate that magnetoencephalography (MEG) recordings can identify functional heterogeneity within a glioma. Functional analysis of these two types of areas has shown that the expression of synaptogenic factors is increased in areas of high functional connectivity compared to areas of low functional connectivity. Areas of high functional connectivity are more aggressive and more resistant to treatment.
In general, gliomas are characterized by a high degree of inter- and intra-tumoral heterogeneity. The latter has been well characterized at the transcriptomic level, and several distinct cell subpopulations have been described (classical, mesenchymal, proneural) This intra-tumoral heterogeneity is one of the factors contributing to resistance to current therapies, but it remains incompletely understood and explored. MEG is a tool capable of exploring intra- and inter-tumor heterogeneity from an electrophysiological perspective. This represents an original approach that will provide a better understanding of intra-tumor heterogeneity and lead to new therapeutic perspectives.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Bron, 69800, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eligible patients will undergo a complete Magnetoencephalography, of approximatively 45min
Time frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
Percentage of patients with a complete and usable magnetoencephalography (MEG) recording, allowing intra- and peri-tumoral electrophysiological data to be collected and resting functional connectivity to be studied for all areas of the brain.
Time frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
Radiological patterns of areas identified by MEG, based on preoperative brain Magnetic resonance imaging (MRI) (morphological and functional)
Time frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
Survival of patients with residual High Frequency Channel/ Low Frequency Channel (HFC/LFC) areas on postoperative MRI and survival of patients without such areas.
Contact information is provided by the study sponsor or research team.
Julien BERTHILLER
CONTACT
Thiébaud PICART
CONTACT
Hospices Civils de Lyon
Other
Acronym: GLIOMEG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07206849
Brain Diseases, Brain Neoplasms
View Trial DetailsNCT07725640
Glioma, High-Grade Glioma (HGG)
Barcelona, Spain
View Trial DetailsNCT07703605
Brain Diseases, Brain Neoplasms
View Trial DetailsNCT07664176
Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Brain Diseases
View Trial Details